Roots Analysis

MARCH 2, 2022

Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Over 40 oral drug delivery technologies have been designed so far. Pipeline Overview of Oral Peptide and Protein-based Therapeutics.

Protein 52

Protein Drug Delivery Drugs Drug Delivery Systems 52

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Future Evolution of Biopharmaceutical Excipient Manufacturing Market.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

MAY 21, 2024

Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

XTalks

AUGUST 30, 2022

CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?

Trials 83

Trials Drug Delivery Drugs Gene 83